Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Lallemant

Showing results (31-40 of 97) with videos related to

Pageof 10
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2008
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected childrenTim R Cressey, Hannah Green, Saye Khoo, et al.
Therapeutic Drug Monitoring|January 15, 2011
Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavirTim R Cressey, Saik Urien, Deborah Hirt, et al.
The New England Journal of Medicine|July 13, 2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in ThailandMarc Lallemant, Gonzague Jourdain, Sophie Le Coeur, et al.
The Pediatric Infectious Disease Journal|March 29, 2006
Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmissionNelly Briand, Sophie Le Coeur, Patrinee Traisathit, et al.
The Lancet. HIV|December 12, 2018
Lopinavir-ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir-ritonavir without rifampicin: a pharmacokinetic modelling and clinical studyHelena Rabie, Paolo Denti, Janice Lee, et al.
Antiviral Therapy|March 27, 2009
Perinatal zidovudine prophylaxis in HIV type-1-infected pregnant women with thalassaemia carriage in ThailandNelly Briand, Sakorn Pornprasert, Nicole Ngo-Giang-Huong, et al.
British Journal of Clinical Pharmacology|July 14, 2021
Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medicationsTjokosela Tikiso, Helen McIlleron, David Burger, et al.
Antiviral Therapy|April 30, 2016
Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected childrenAdeodata Kekitiinwa, Victor Musiime, Margaret J Thomason, et al.
The New England Journal of Medicine|July 13, 2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapyGonzague Jourdain, Nicole Ngo-Giang-Huong, Sophie Le Coeur, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 16, 2013
Five-year trends in antiretroviral usage and drug costs in HIV-infected children in ThailandIntira Collins, John Cairns, Sophie Le Coeur, et al.
Pageof 10

Showing results (31-40 of 97) with videos related to

Sort By:
Pageof 10
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2008
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected childrenTim R Cressey, Hannah Green, Saye Khoo, et al.
Therapeutic Drug Monitoring|January 15, 2011
Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavirTim R Cressey, Saik Urien, Deborah Hirt, et al.
The New England Journal of Medicine|July 13, 2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in ThailandMarc Lallemant, Gonzague Jourdain, Sophie Le Coeur, et al.
The Pediatric Infectious Disease Journal|March 29, 2006
Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmissionNelly Briand, Sophie Le Coeur, Patrinee Traisathit, et al.
The Lancet. HIV|December 12, 2018
Lopinavir-ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir-ritonavir without rifampicin: a pharmacokinetic modelling and clinical studyHelena Rabie, Paolo Denti, Janice Lee, et al.
Antiviral Therapy|March 27, 2009
Perinatal zidovudine prophylaxis in HIV type-1-infected pregnant women with thalassaemia carriage in ThailandNelly Briand, Sakorn Pornprasert, Nicole Ngo-Giang-Huong, et al.
British Journal of Clinical Pharmacology|July 14, 2021
Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medicationsTjokosela Tikiso, Helen McIlleron, David Burger, et al.
Antiviral Therapy|April 30, 2016
Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected childrenAdeodata Kekitiinwa, Victor Musiime, Margaret J Thomason, et al.
The New England Journal of Medicine|July 13, 2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapyGonzague Jourdain, Nicole Ngo-Giang-Huong, Sophie Le Coeur, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 16, 2013
Five-year trends in antiretroviral usage and drug costs in HIV-infected children in ThailandIntira Collins, John Cairns, Sophie Le Coeur, et al.
Pageof 10